A Phase II Study of AT7519M, A CDK Inhibitor in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia.
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2016
At a glance
- Drugs AT 7519 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 15 Feb 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
- 07 Feb 2014 Planned End Date changed from 1 Jul 2014 to 1 Dec 2014 according to ClinicalTrials.gov record.
- 22 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.